REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA.
Details of the presentations are as follows:
2022 Endocrine Society Meeting (ENDO)
| Title: | Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome |
| Format: | Oral Presentation |
| Presenter: | Dr. Eric Felner on behalf of the DESTINY PWS Investigators and Soleno Therapeutics |
| Date: | Sunday, June 12, 2022 |
| Time: | 11 AM to 12:30 PM Eastern Time |
| Title: | Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome |
| Format: | Poster |
| Presenter: | Dr. Michael Woloschak on behalf of the DESTINY PWS Investigators and Soleno Therapeutics |
| Date: | Sunday, June 12, 2022 |
| Time: | 1:00 PM ET |
The copy of the presentation materials will be available in the Investors section on the Company’s website at www.soleno.life after presentation at the meeting.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578